Search
AK104 Approved for First-Line Therapy in Advanced Cervical Cancer, Expanding Treatment Options
2025-06-05 /
Read about 0 minute
Author：小编
Akeso Biopharma's independently developed PD-1/CTLA-4 bispecific tumor immunotherapy drug, AK104, has garnered approval for a groundbreaking new indication as a first-line therapy for persistent, recurrent, or metastatic cervical cancer. This approval allows for AK104 to be administered in combination with platinum-based chemotherapy and bevacizumab, further enhancing its therapeutic potential. Prior to this, AK104 had already been approved for the treatment of patients with recurrent or metastatic cervical cancer. The approval is underpinned by the promising results of the AK104-303/COMPASSION-16 study, which demonstrated substantial benefits of the AK104 regimen across the entire patient cohort.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
